LIXTE's Oncology Platform Expansion: Building Complementary Modalities

LIXTE, a biotech company, has shifted its strategy to build an oncology platform around complementary modalities, including radiotherapy. The acquisition of Liora Technologies brings a radiotherapy system, the LiGHT System, with a smaller footprint, lower infrastructure cost, and adaptable design. This expansion supports LIXTE's goal of broadening its asset base and diversifying its value delivery. The addition of radiotherapy complements LIXTE's systemic therapy and enhances its ability to build momentum across multiple fronts.